NO20054526L - Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen - Google Patents
Forebygging og behandling av brystkreft med 4-hydroxy tamoxifenInfo
- Publication number
- NO20054526L NO20054526L NO20054526A NO20054526A NO20054526L NO 20054526 L NO20054526 L NO 20054526L NO 20054526 A NO20054526 A NO 20054526A NO 20054526 A NO20054526 A NO 20054526A NO 20054526 L NO20054526 L NO 20054526L
- Authority
- NO
- Norway
- Prior art keywords
- breast cancer
- treatment
- cancer prevention
- hydroxy tamoxifen
- hydroxytamoxifen
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 4
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 4
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 title abstract 2
- 230000002265 prevention Effects 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- TXUZVZSFRXZGTL-QPLCGJKRSA-N afimoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=C(O)C=C1 TXUZVZSFRXZGTL-QPLCGJKRSA-N 0.000 abstract 1
- 230000001833 anti-estrogenic effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Foreliggende oppfinnelse fremskaffer fremgangsmåter for behandling og forhindring av brystkreft ved adminisfrering av 4-hydroksytamoxifen til en pasient. Den fremskaffer også farmasøytiske sammensetninger av 4-hydroksytamoxifen som passer for perkutan adminisfrasjon. Når perkutant adminisfrert til en pasients bryst, konsentteres hydroksytamoxifen lokalt og utøver en anti-østtogenisk effekt. I pasienter med brystcancer reduserer denne effekten tumorproliferasjonen. I pasienter med risiko for utvikling av brystcancer, forhindrer den anti-østtogene effekten dannelse av tumorer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45896303P | 2003-04-01 | 2003-04-01 | |
PCT/EP2003/015029 WO2004087123A1 (en) | 2003-04-01 | 2003-12-15 | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20054526L true NO20054526L (no) | 2005-09-30 |
NO333805B1 NO333805B1 (no) | 2013-09-16 |
Family
ID=33131847
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20054526A NO333805B1 (no) | 2003-04-01 | 2005-09-30 | Anvendelse av 4-hydroxy tamoxifen for fremstilling av et medikament, og farmasoytiske sammensetninger |
Country Status (12)
Country | Link |
---|---|
US (2) | US7704516B2 (no) |
EP (3) | EP1952810B1 (no) |
JP (1) | JP5490346B2 (no) |
AU (1) | AU2003294973B2 (no) |
CA (1) | CA2519980C (no) |
ES (3) | ES2456958T3 (no) |
HK (2) | HK1086193A1 (no) |
IL (1) | IL170807A (no) |
MX (1) | MXPA05010597A (no) |
NO (1) | NO333805B1 (no) |
NZ (1) | NZ542499A (no) |
WO (1) | WO2004087123A1 (no) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO337298B1 (no) * | 2004-03-22 | 2016-03-07 | Besins Healthcare Lu Sarl | Kjemisk stabile preparater av 4-hydroksytamoksifen |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60327363D1 (de) * | 2002-12-18 | 2009-06-04 | Besins Int Lab | Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen |
AU2003294973B2 (en) * | 2002-12-18 | 2010-05-13 | Besins Healthcare Luxembourg Sarl | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
AU2003303033B2 (en) * | 2002-12-18 | 2009-06-04 | Besins Healthcare Luxembourg Sarl | Treatment of mastalgia with 4-hydroxy tamoxifen |
CA2528431C (en) * | 2003-06-09 | 2012-09-18 | Northwestern University | Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen |
US7968532B2 (en) * | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
EP1579856A1 (en) * | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
US7507769B2 (en) | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
PT1748770E (pt) * | 2004-03-22 | 2008-07-16 | Besins Int Lab | Tratamento e prevenção de doença benigna da mama com 4-hidroxi-tamoxifeno |
ATE415156T1 (de) * | 2004-10-14 | 2008-12-15 | Besins Int Lab | 4-hydroxytamoxifengel-formulierungen |
EP1647271A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
EP2147674A1 (en) * | 2008-07-24 | 2010-01-27 | Besins Healthcare | Transdermal pharmaceutical compositions comprising danazol |
US10080760B2 (en) * | 2009-10-27 | 2018-09-25 | Besins Healthcare Luxembourg Sarl | Transdermal pharmaceutical compositions comprising active agents |
CA2948823C (en) | 2014-05-12 | 2020-09-22 | Quest Diagnostics Investments Incorporated | Quantitation of tamoxifen and metabolites thereof by mass spectrometry |
KR101571098B1 (ko) | 2014-07-16 | 2015-11-23 | 건국대학교 산학협력단 | 타목시펜 및 메틸설포닐메탄을 유효성분으로 포함하는 암 질환 예방 또는 치료용 약학 조성물 |
KR102178215B1 (ko) * | 2014-08-27 | 2020-11-12 | 도요보 가부시키가이샤 | 저유전 접착제 조성물 |
EP3230478B1 (en) * | 2014-12-12 | 2023-08-02 | Miradx | Methods for treating or preventing cancer in a kras-variant patient and for diagnosing risk of developing multiple primary breast tumors |
EP3449017B1 (en) | 2016-04-29 | 2021-12-22 | Board of Regents, The University of Texas System | Targeted measure of transcriptional activity related to hormone receptors |
MX2020002649A (es) | 2017-09-11 | 2020-09-25 | Atossa Therapeutics Inc | Metodos para hacer y usar endoxifeno. |
WO2019172109A1 (ja) | 2018-03-07 | 2019-09-12 | 東亞合成株式会社 | 接着剤組成物及びこれを用いた接着剤層付き積層体 |
WO2020023616A1 (en) * | 2018-07-24 | 2020-01-30 | Cornell University | Methods of upregulating tiparp as anticancer strategies |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2558373B1 (fr) * | 1984-01-20 | 1987-07-03 | Mauvais Jarvis Pierre | Medicament antioestrogene a base de 4-hydroxytamoxifene pour administration percutanee |
ATE80152T1 (de) * | 1987-04-21 | 1992-09-15 | Heumann Pharma Gmbh & Co | Stabile loesungsmitteladdukte von z-1-(p-betadimethylamino-ethoxyphenyl)-1-(p-hydroxyphenyl) 2-phenylbut-1-en. |
US5045553A (en) | 1987-06-24 | 1991-09-03 | Fujisawa Pharmaceutical Company, Ltd. | Pharmaceutical composition for percutaneous drug absorption and percutaneous drug absorption promoter |
DE3836862A1 (de) | 1988-10-27 | 1990-05-03 | Schering Ag | Mittel zur transdermalen applikation von steroidhormonen |
US5189212A (en) | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
TW218849B (no) * | 1991-05-17 | 1994-01-11 | Bristol Myers Squibb Co | |
US5613958A (en) * | 1993-05-12 | 1997-03-25 | Pp Holdings Inc. | Transdermal delivery systems for the modulated administration of drugs |
DE4407742C1 (de) * | 1994-03-08 | 1995-06-22 | Hexal Pharma Gmbh | Transdermales System in Form eines Pflasters mit einem Tamoxifen-Derivat |
US5720963A (en) * | 1994-08-26 | 1998-02-24 | Mary Kay Inc. | Barrier disruption treatments for structurally deteriorated skin |
WO1997036570A1 (de) * | 1996-03-29 | 1997-10-09 | S.W. Patentverwertungs Ges. M.B.H. Edelsbacher U. Partner | Kosmetikum bzw. kosmetikzusammensetzung zur glättung und straffung der haut bei gestörtem unterhaut-binde-fettgewebe, insbesondere bei der 'cellulite' |
JP2001527037A (ja) | 1997-12-23 | 2001-12-25 | ヘキサル アーゲー | Z−4−ヒドロキシタモキシフェン及びシクロデキストリンを含む混合物及び薬剤学的組成 |
US6013270A (en) * | 1998-04-20 | 2000-01-11 | The Procter & Gamble Company | Skin care kit |
ES2239057T3 (es) | 1999-12-16 | 2005-09-16 | Dermatrends, Inc. | Agentes de liberacion de hidroxido utilizados como potenciadores de la permeacion cutanea. |
DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
US20040198706A1 (en) | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
US6503894B1 (en) * | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
AU2002340120A1 (en) | 2001-10-04 | 2003-04-14 | Cellegy Pharmaceuticals, Inc. | Semisolid topical hormonal compositions and methods for treatment |
ES2330188T3 (es) * | 2001-12-07 | 2009-12-07 | Besins Manufacturing Belgium | Composicion farmaceutica en forma de gel o de solucion a base de dihidrotestoterona, su procedimiento de preparacion y sus utilizaciones. |
AU2003303033B2 (en) * | 2002-12-18 | 2009-06-04 | Besins Healthcare Luxembourg Sarl | Treatment of mastalgia with 4-hydroxy tamoxifen |
DE60327363D1 (de) * | 2002-12-18 | 2009-06-04 | Besins Int Lab | Verringerung der dichte des brustgewebes durch 4-hydroxy tamoxifen |
AU2003294973B2 (en) | 2002-12-18 | 2010-05-13 | Besins Healthcare Luxembourg Sarl | Prevention and treatment of breast cancer with 4-hydroxy tamoxifen |
CA2528431C (en) * | 2003-06-09 | 2012-09-18 | Northwestern University | Treatment and prevention of excessive scarring with 4-hydroxy tamoxifen |
US7968532B2 (en) * | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
US7507769B2 (en) * | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
EP1579857A1 (en) | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Chemically stable compositions of 4-hydroxy tamoxifen |
EP1579856A1 (en) | 2004-03-22 | 2005-09-28 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
EP1647271A1 (en) * | 2004-10-14 | 2006-04-19 | Laboratoires Besins International | 4-Hydroxy tamoxifen gel formulations |
-
2003
- 2003-12-15 AU AU2003294973A patent/AU2003294973B2/en not_active Expired
- 2003-12-15 JP JP2004570040A patent/JP5490346B2/ja not_active Expired - Lifetime
- 2003-12-15 EP EP08103007.4A patent/EP1952810B1/en not_active Expired - Lifetime
- 2003-12-15 MX MXPA05010597A patent/MXPA05010597A/es active IP Right Grant
- 2003-12-15 CA CA2519980A patent/CA2519980C/en not_active Expired - Lifetime
- 2003-12-15 US US10/734,638 patent/US7704516B2/en not_active Expired - Lifetime
- 2003-12-15 EP EP03785958.4A patent/EP1608353B1/en not_active Expired - Lifetime
- 2003-12-15 ES ES08103014.0T patent/ES2456958T3/es not_active Expired - Lifetime
- 2003-12-15 EP EP08103014.0A patent/EP1941871B1/en not_active Expired - Lifetime
- 2003-12-15 NZ NZ542499A patent/NZ542499A/en not_active IP Right Cessation
- 2003-12-15 WO PCT/EP2003/015029 patent/WO2004087123A1/en active Application Filing
- 2003-12-15 ES ES08103007.4T patent/ES2456957T3/es not_active Expired - Lifetime
- 2003-12-15 ES ES03785958.4T patent/ES2483896T3/es not_active Expired - Lifetime
-
2005
- 2005-09-12 IL IL170807A patent/IL170807A/en active IP Right Grant
- 2005-09-30 NO NO20054526A patent/NO333805B1/no not_active IP Right Cessation
-
2006
- 2006-06-28 HK HK06107310.2A patent/HK1086193A1/xx not_active IP Right Cessation
- 2006-06-28 HK HK08113909.5A patent/HK1119950A1/xx not_active IP Right Cessation
-
2009
- 2009-01-14 US US12/353,890 patent/US8475814B2/en active Active
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO337298B1 (no) * | 2004-03-22 | 2016-03-07 | Besins Healthcare Lu Sarl | Kjemisk stabile preparater av 4-hydroksytamoksifen |
Also Published As
Publication number | Publication date |
---|---|
NZ542499A (en) | 2008-10-31 |
ES2456957T3 (es) | 2014-04-24 |
EP1952810A1 (en) | 2008-08-06 |
ES2456958T3 (es) | 2014-04-24 |
US7704516B2 (en) | 2010-04-27 |
US8475814B2 (en) | 2013-07-02 |
AU2003294973B2 (en) | 2010-05-13 |
CA2519980A1 (en) | 2004-10-14 |
CA2519980C (en) | 2012-04-10 |
HK1086193A1 (en) | 2006-09-15 |
EP1952810B1 (en) | 2014-01-08 |
EP1941871B1 (en) | 2014-01-08 |
US20090186944A1 (en) | 2009-07-23 |
NO333805B1 (no) | 2013-09-16 |
JP5490346B2 (ja) | 2014-05-14 |
US20050031695A1 (en) | 2005-02-10 |
EP1608353A1 (en) | 2005-12-28 |
IL170807A (en) | 2014-08-31 |
ES2483896T3 (es) | 2014-08-08 |
WO2004087123A1 (en) | 2004-10-14 |
AU2003294973A1 (en) | 2004-10-25 |
MXPA05010597A (es) | 2006-03-09 |
EP1608353B1 (en) | 2014-04-30 |
HK1119950A1 (en) | 2009-03-20 |
JP2006514967A (ja) | 2006-05-18 |
EP1941871A1 (en) | 2008-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20054526L (no) | Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen | |
IL244727A0 (en) | Methods and preparations using immunomodulatory compounds for the treatment and management of cancer and other diseases | |
BR0209147A (pt) | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais | |
BR0316685A (pt) | Composições e métodos para a administração aperfeiçoada por via mucosal de peptìdeos fixadores ao receptor de y2 e métodos para tratar e prevenir a obesidade | |
MXPA05012155A (es) | Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades. | |
TW200500355A (en) | Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases | |
EP1933833B8 (en) | Therapy for the treatment of overactive bladder | |
NO20070702L (no) | Kombinasjonsbehandling for ikke-hematologisk malignitet ved anvendelse av anti-OGF-1R antistoff | |
BRPI0512213A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
DK1169059T3 (da) | Docetaxel i kombination med rhuMAb HER2 til behandling af cancere | |
BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
RU2007138867A (ru) | Режимы дозирования транс-кломифена | |
BRPI0414736A (pt) | 5-aril-pirimidinas como agentes anticáncer | |
BR112022010806A2 (pt) | Métodos para tratar câncer de mama, para inibir o crescimento tumoral e para prevenir ou retardar o desenvolvimento de resistência de um câncer de mama | |
RU2011151854A (ru) | Новые терапевтические способы применения инекальцитола | |
EA201270298A1 (ru) | Способ лечения злокачественной опухоли | |
NO20062904L (no) | Anvendelse av 4-hydroksy tamoxifen for fremstilling av et medikament for behandling av gynekomasti | |
WO2002074756A3 (de) | Urokinase-inhibitoren | |
BR112022001814A2 (pt) | Métodos de tratamento de câncer multifocal | |
NO20064609L (no) | Behandling og forhindring av godartet brystsykdom med 4-hydroksytamoksifen | |
MX2010006310A (es) | O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor. | |
RU2519120C1 (ru) | Способ профилактики скелетных осложнений у больных с литическими метастазами в плоские и смешанные кости | |
ATE354373T1 (de) | Verabreichung von gammaglobulinen zur behandlung von lymphomen | |
Vidal et al. | Triton tumor in a patient with neurofibromatosis-1: a clinical case | |
Prescott | Improving therapy for prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BESINS HEALTHCARE LUXEMBOURG, LU |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BENSINS HEALTHCARE LUXEMBOURG SARL, LU |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: BESINS HEALTHCARE LUXEMBOURG SARL, LU |
|
MK1K | Patent expired |